A judge in a Delaware district court ruled that defendants in a patent suit involving Avanir’s (AVNR) Nudexta, including Impax (NASDAQ:IPXL) and Par Pharmaceutical (PRX), must provide notice of any FDA approval for its ANDA product to the other parties in the suit and the court within four hours of receipt of such approval. Impax Laboratories Inc. (NASDAQ:IPXL) shares after opening at $25.70 moved to $26.09 on last trade day and at the end of the day closed at $24.77. Company price to sales ratio in past twelve months was calculated as 3.38 and price to cash ratio as 4.18. Impax Laboratories Inc. (NASDAQ:IPXL) showed a negative weekly performance of -6.28%.
China Pharma Holdings, Inc. (NYSEMKT:CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, announced on march 21 updated dial-in information for its fiscal year 2013 earnings conference call. (NYSEMKT:CPHI) shares advanced 0.42% in last trading session and ended the day on $0.500. CPHI return on equity ratio is recorded as -7.40% and its return on assets is -6.70%. China Pharma Holdings, Inc. (NYSEMKT:CPHI) yearly performance is 72.41%.
On Mar 27, 2014 Retrophin, Inc. (NASDAQ:RTRX) reported its financial results for the year ended December 31, 2013. Retrophin Inc. (NASDAQ:RTRX) shares moved up 1.02% in last trading session and was closed at $19.75, while trading in range of $19.41 – $20.76. Retrophin Inc. (NASDAQ:RTRX) year to date (YTD) performance is 182.14%.
Novartis AG (ADR) (NYSE:NVS) said it will ask global regulators for approval of a drug for chronic heart failure earlier than expected, bolstering its plan to build a portfolio of treatments for the disease. Novartis AG (ADR) (NYSE:NVS) weekly performance is -0.17%. On last trading day company shares ended up $81.59. Novartis AG (ADR) (NYSE:NVS) distance from 50-day simple moving average (SMA50) is 2.04%. Analysts mean target price for the company is $83.51.